人工智能辅助的容积各向同性同时交错亮血和黑血成像用于脑转移瘤检测
回顾性纳入40例患者(20例有脑转移、20例无),7名独立观察者(3名放射科住院医师和4名神经放射学家)分两阶段读片:仅用VISIBLE检测脑转移瘤,再综合加入AI-VISIBLE信息评估。AI-VISIBLE将敏感度从88.3±5.1%提升至94.9±1.7%(P=0.0028),FOM从0.972±0.013提升至0.983±0.009(P=0.0063),假阳性/例无显著差异(P=0.250)。
要点
- AI-VISIBLE较单独VISIBLE显著提高脑转移瘤检测敏感度(94.9±1.7% vs. 88.3±5.1%,P=0.0028)。
- 加入AI信息后诊断性能FOM显著提高(0.983±0.009 vs. 0.972±0.013,P=0.0063)。
- 有无AI信息假阳性/例无显著差异(0.23±0.19 vs. 0.18±0.15,P=0.250)。
核心结论
- AI-VISIBLE提高了脑转移瘤的诊断敏感度和诊断性能。
研究设计与样本
- 回顾性研究,经机构审查委员会批准并豁免书面知情同意,纳入40例患者(20例有脑转移、20例无脑转移),7名独立观察者(3名放射科住院医师和4名神经放射学家)参与两阶段读片。
诊断标准与关键数值
- 敏感度:VISIBLE加AI信息为94.9±1.7%,不加AI信息为88.3±5.1%(P=0.0028)。
- 诊断性能FOM:VISIBLE加AI信息为0.983±0.009,不加AI信息为0.972±0.013(P=0.0063)。
- 假阳性/例:加AI信息为0.23±0.19,不加AI信息为0.18±0.15(P=0.250),无显著差异。
- 放射科住院医师加AI信息后敏感度94.8±1.3%、FOM 0.977±0.010,与神经放射学家加AI信息后的敏感度95.0±2.1%、FOM 0.988±0.005相当;不加AI信息时住院医师敏感度85.9±3.4%、FOM 0.969±0.016,神经放射学家敏感度90.0±5.9%、FOM 0.974±0.012。
临床应用与阅片要点
- 在日常阅片和报告中,可参照本研究的读片流程:先单独判读VISIBLE,再综合AI-VISIBLE信息复核,以提高脑转移瘤的检出敏感度且不增加假阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To verify the effectiveness of artificial intelligence-assisted volume isotropic simultaneous interleaved bright-/black-blood examination (AI-VISIBLE) for detecting brain metastases.
METHODS: This retrospective study was approved by our institutional review board and the requirement for written informed consent was waived. Forty patients were included: 20 patients with and without brain metastases each. Seven independent observers (three radiology residents and four neuroradiologists) participated in two reading sessions: in the first, brain metastases were detected using VISIBLE only; in the second, the results of the first session were comprehensively evaluated by adding AI-VISIBLE information. Sensitivity, diagnostic performance, and false positives/case were evaluated. Diagnostic performance was assessed using a figure-of-merit (FOM). Sensitivity and false positives/case were evaluated using McNemar and paired t-tests, respectively.
RESULTS: The McNemar test revealed a significant difference between VISIBLE with/without AI information (P < 0.0001). Significantly higher sensitivity (94.9 ± 1.7% vs. 88.3 ± 5.1%, P = 0.0028) and FOM (0.983 ± 0.009 vs. 0.972 ± 0.013, P = 0.0063) were achieved using VISIBLE with AI information vs. without. No significant difference was observed in false positives/case with and without AI information (0.23 ± 0.19 vs. 0.18 ± 0.15, P = 0.250). AI-assisted results of radiology residents became comparable to results of neuroradiologists (sensitivity, FOM: 85.9 ± 3.4% vs. 90.0 ± 5.9%, 0.969 ± 0.016 vs. 0.974 ± 0.012 without AI information; 94.8 ± 1.3% vs. 95.0 ± 2.1%, 0.977 ± 0.010 vs. 0.988 ± 0.005 with AI information, respectively).
CONCLUSION: AI-VISIBLE improved the sensitivity and performance for diagnosing brain metastases.
引用
- Kikuchi K, Togao O, Kikuchi Y, et al. Artificial intelligence-assisted volume isotropic simultaneous interleaved bright- and black-blood examination for brain metastases. Neuroradiology. 2024. PMID: 39172167. doi:10.1007/s00234-024-03454-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。